Currently in Phase 1 clinical trials in the U.S., SB1518 is a small molecule JAK2-selective kinase inhibitor which has high potency against both the wild type JAK2 kinase and the JAK2 kinase with the V617F mutation. The V617F mutation is found in high frequencies in certain types of hematological disorders. By targeting the JAK2 activating mutation, SB1518 has the potential to interfere with a key mechanism driving the progress of a variety of cancers and other hematological disorders.
About Bio*One Capital
Bio*One Capital is a leading, dedicated biomedical sciences investment management company in Asia with a worldwide presence. Investments are focused on promising and innovative global biomedical companies where Bio*One Capital can play a value adding role in bridging and supporting companies' growth strategies in Asia through their operations in Singapore. A part of the Singapore Economic Development Board, Bio*One Capital oversees a portfolio of over 50 companies in US, Europe, Singapore and Asia. For more information, please visit http://www.bio1capital.com.
About Aravis Venture
Aravis Venture, founded in 2001, is an international venture capital
group focusing on private biotech and renewable energy companies with
presence in Cayman, Switzerland, Singapore and Menlo Park, California. The
Aravis investment team is comprised of 13 partners, investment experienced
leading scientists, venture capitalists and operating executives who have
been involved with the successful financing, growth and realization of more
than 80 companies worldwide over the last 20 years. With the combined know
how of scientific/technical expertise and management, Aravis seeks to add
value to its investments by actively participating in the buildup and
growth of its portfolio companies. For more information, please
|SOURCE S*BIO Pte Ltd|
Copyright©2008 PR Newswire.
All rights reserved